These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mycosis fungoides and the Sézary syndrome. Kim YH; Hoppe RT Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085 [TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880 [TBL] [Abstract][Full Text] [Related]
4. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis. Smith BD; Wilson LD Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854 [TBL] [Abstract][Full Text] [Related]
5. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425 [TBL] [Abstract][Full Text] [Related]
6. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome. Suzuki SY; Ito K; Ito M; Kawai K J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424 [TBL] [Abstract][Full Text] [Related]
7. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG; Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564 [TBL] [Abstract][Full Text] [Related]
8. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822 [TBL] [Abstract][Full Text] [Related]
9. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Wain EM; Orchard GE; Whittaker SJ; Spittle M Sc MF; Russell-Jones R Cancer; 2003 Nov; 98(10):2282-90. PubMed ID: 14601100 [TBL] [Abstract][Full Text] [Related]
10. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308 [TBL] [Abstract][Full Text] [Related]
12. Mycosis fungoides--a review of the management of 28 patients and of the recent literature. Lenane P; Powell FC; O'Keane C; Dervan P; O'Sullivan D; Bourke E; O'Loughlin S Int J Dermatol; 2007 Jan; 46(1):19-26. PubMed ID: 17214715 [TBL] [Abstract][Full Text] [Related]
13. Disease evolution of patients with mycosis fungoides--a report of 30 cases. Berlingeri-Ramos AC; De Jesús G; Sánchez JL; González JR P R Health Sci J; 2007 Jun; 26(2):151-4. PubMed ID: 17722429 [TBL] [Abstract][Full Text] [Related]
14. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings. Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144 [TBL] [Abstract][Full Text] [Related]
15. Mycosis fungoides--analysis of the duration of disease stages in patients who progress and the time point of high-grade transformation. Kamarashev J; Theler B; Dummer R; Burg G Int J Dermatol; 2007 Sep; 46(9):930-5. PubMed ID: 17822495 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. de Coninck EC; Kim YH; Varghese A; Hoppe RT J Clin Oncol; 2001 Feb; 19(3):779-84. PubMed ID: 11157031 [TBL] [Abstract][Full Text] [Related]
17. A modified staging classification for cutaneous T-cell lymphoma. Kashani-Sabet M; McMillan A; Zackheim HS J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Kim YH; Bishop K; Varghese A; Hoppe RT Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601 [TBL] [Abstract][Full Text] [Related]
19. [Prognosis of primary cutaneous lymphomas]. Grange F; Bagot M Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):30-40. PubMed ID: 11937927 [TBL] [Abstract][Full Text] [Related]
20. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. Wilson LD; Jones GW; Kim D; Rosenthal D; Christensen IR; Edelson RL; Heald PW; Kacinski BM J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):54-60. PubMed ID: 10863224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]